A Phase 2a Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525817-29-00

Enrollment

Registered

2026-06-05

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis; Primary Progressive Multiple Sclerosis; non-active Secondary Progressive Multiple Sclerosis

Brief summary

Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) Time Frame: From enrollment to the end of study at 16 weeks

Detailed description

Markers of disease in blood and brain fluid as well as imaging to measure inflammation Time Frame: from enrollment to the end of treatment at 12 weeks

Interventions

DRUGSUN-627

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) Time Frame: From enrollment to the end of study at 16 weeks	—

Secondary

Measure	Time frame
Markers of disease in blood and brain fluid as well as imaging to measure inflammation Time Frame: from enrollment to the end of treatment at 12 weeks	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 6, 2026